
Rockwell Medical, Inc.
RMTINASDAQHealthcareDrug Manufacturers - Specialty & Generic
Latest quote
$8.01
+$0.46 · +6.02%
RMTI company overview
Regular session · ET · Market data may be delayed.
GoAI snapshot
AI-powered factor overview
GoAI score
Sell
Trim exposure — unfavorable risk-reward
Valuation
50
Fair Value
Momentum
17
Strong Down
Sentiment
59
Mixed
Risk resilience
23
High Risk
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
AI-generated, informational only, and not investment advice.
Company profile
Company websiteRockwell Medical, Inc., together with its associated companies, operates as a biopharmaceutical firm specializing in treatments for chronic and end-stage kidney disease. The company provides a range of therapies and products aimed at addressing iron deficiency and supporting hemodialysis procedures, serving markets both within the United States and internationally. A key offering includes its Triferic line (Triferic Dialysate and Triferic AVNU), an innovative iron replacement therapy. This therapy is designed to replenish iron and maintain healthy hemoglobin levels in dialysis patients, notably without increasing existing iron stores. Beyond iron management, Rockwell Medical manufactures, sells, and distributes a comprehensive range of hemodialysis concentrates. These include various acid concentrates such as CitraPure (citric), Dri-Sate (dry), and RenalPure (liquid), alongside a dry acid concentrate mixer, and powder bicarbonate concentrates like RenalPure and SteriLyte. These crucial products are vital for sustaining life in dialysis patients by facilitating the removal of toxins and the replacement of essential nutrients in their bloodstream. The company further supplies ancillary items critical for hemodialysis procedures. This extensive catalog comprises blood tubing, fistula needles, dialyzers, pharmaceuticals, specialized component kits, dressings, cleaning agents, filtration salts, and other necessary provisions utilized by hemodialysis providers. Looking to the future, Rockwell Medical is actively developing additional therapeutic candidates. These include treatments for hospitalized individuals suffering from acute heart failure, as well as solutions for home infusion therapy, enabling patients to receive intravenous medications in a home setting. The company primarily serves medium and small-sized dialysis chains, as well as independent dialysis centers. Established in 1996, Rockwell Medical, Inc. maintains its corporate headquarters in Wixom, Michigan.
- Industry
- Drug Manufacturers - Specialty & Generic
- Sector
- Healthcare
- Headquarters
- US
- CEO
- Mark Strobeck
- Listed since
- Jan 27, 1998
- Employees
- 157
Market position
- Volume
- 25.81K
- 0.77× average
- Average volume
- 33.53K
- Average daily volume
- Market cap
- 31.97M USD
- Beta
- 1.62
- Market reference 1
Financials
Financial statements
Margin trends
Profitability as a percentage of reported revenue.
Income trends
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 69.26M USD | 101.49M USD | 83.61M USD | 72.81M USD | 61.93M USD |
| Cost of goods sold | 57.56M USD | 84.01M USD | 74.91M USD | 68.73M USD | 64.35M USD |
| Gross profit | 11.7M USD | 17.48M USD | 8.7M USD | 4.08M USD | −2.42M USD |
| Research and development | — | 19K USD | 1.11M USD | 3.12M USD | 6.84M USD |
| Selling, general, and administrative | 16.39B USD | 16.86M USD | 14.27M USD | 17.74M USD | 21.08M USD |
| Operating expenses | 16.39M USD | 16.88M USD | 15.37M USD | 20.86M USD | 27.92M USD |
| Interest income | 234K USD | 92K USD | 211K USD | 33K USD | 22K USD |
| Interest expense | 1.12M USD | 1.25M USD | 2.3M USD | 1.94M USD | 2.36M USD |
| Depreciation and amortization | 2.19M USD | 2.18M USD | 1.44M USD | 576K USD | 2.52M USD |
| Operating income | −4.69M USD | 608K USD | −6.67M USD | −16.78M USD | −30.34M USD |
| Net income | −5.31M USD | −480K USD | −8.44M USD | −18.68M USD | −32.67M USD |
Company facts updated Aug 24, 2026.
Analyst ratings
Third-party consensus; not a GoAI recommendation.
Rating distribution
16 ratingsRecent analyst actions
RMTI news
RMTI peers
ETFs holding RMTI
Funds reporting this stock among their holdings, ordered by reported position size.
Continue in GoAI
Research RMTIresearch.disclaimer













